QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pai, M. P Articles by Pendland, S. L Search for Related Content PubMed PubMed Citation Articles by Pai, M. P Articles by Pendland, S. L

INFECTIOUS DISEASES

Antifungal Susceptibility Testing in Teaching Hospitals

Assistant Professor, College of Pharmacy, University of New Mexico, Albuquerque, NM

Susan L Pendland, MS PharmD

Assistant Professor, Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, IL

Reprints: Susan L Pendland MS PharmD, Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, 833 S. Wood St., Rm. 112A, Chicago, IL 60612-7230, FAX 312/413-1797, E-mail pendland{at}uic.edu

BACKGROUND: An assessment of antifungal susceptibility testing (AST) has not been conducted since the introduction of the National Committee for Clinical Laboratory Standards (NCCLS) M27-A document.

OBJECTIVE: To determine AST practices in teaching hospitals.

METHODS: A questionnaire was mailed to the heads of 386 randomly assigned microbiology departments from teaching hospitals identified through the 2000 American Hospital Association Guide. Identifiers were used to delineate responders from nonresponders. A reminder letter was mailed 3 weeks after the initial mailing to all nonresponders. The hospital bed-size and number of inpatient days for respondents were obtained through the American Hospital Directory.

RESULTS: The questionnaire was returned by 171 (44.3%) institutions. The total and median (range) number of candida isolates were 137 088 and 8.5 (1–145)/1000 inpatient days for the year 2000, respectively. Approximately 1% (1300) of candida isolates, from predominantly blood specimens, underwent AST. AST was reported by 115 (67.2%) hospitals, with testing on site at 27 hospitals and off site for 88 hospitals. NCCLS methodology (80% broth microdilution) was used by 75% of the hospitals performing on-site AST. The median time to obtain AST results was significantly lower when testing was performed on site (3 d) compared with off site (7–10 d).

SUMMARY: A large number of candida bloodstream isolates undergoes AST annually. AST results are obtained sooner when performed on site compared with off site.

Key Words: antifungal, Candida spp., susceptibility

Published Online, January 3, 2003. www.theannals.com, DOI

This article has been cited by other articles:

				M. P. Pai, R. S. Turpin, and K. W. Garey Association of Fluconazole Area under the Concentration-Time Curve/MIC and Dose/MIC Ratios with Mortality in Nonneutropenic Patients with Candidemia Antimicrob. Agents Chemother., January 1, 2007; 51(1): 35 - 39. [Abstract] [Full Text] [PDF]

				M. A. Pfaller, D. J. Diekema, and D. J. Sheehan Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing Clin. Microbiol. Rev., April 1, 2006; 19(2): 435 - 447. [Abstract] [Full Text] [PDF]